Spinal Cord Stimulation Trial to Permanent Prediction

Launched by ABBOTT MEDICAL DEVICES · Dec 20, 2022

Keywords

ClinConnect Summary

The study will enroll up to 60 subjects at 10 sites in the United States. Follow-up will continue for a period of 6 months post-trial for subjects who choose not to receive a permanently-implanted system as well as 6 months post implant for subjects receiving a permanent implant.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Subject must provide written informed consent prior to any clinical investigation-related procedure.
• • 2. Subject is at least 18 years of age or older at the time of enrollment.
• • 3. Subject is scheduled to undergo trial of an Abbott neuromodulation system for chronic intractable pain at least 7 days after enrollment and commencement of the baseline data collection period.
• • 4. Subject's scheduled trial duration for the Abbott neuromodulation system is at least 3 days.
• • 5. Subject has a baseline (with no stimulation) pain NRS of ≥ 6.
• • 6. Subject is willing to cooperate with the study requirements including completion of all office visits.
• • 7. Subject agrees to wear the wearable sensing devices (Anne™ patch, Anne™ limb unit, Apple watch®, and Oura™ Ring).
• • 8. Subject agrees to answer questionnaires regularly for the duration of the study.
• Exclusion Criteria:
• • 1. Subject is enrolled, or intends to participate, in a competing or confounding clinical study, as determined by Abbott.
• • 2. Pregnant or nursing subjects and those who plan pregnancy during the clinical investigation follow-up period.
• • 3. Subject is part of a vulnerable population.
• • 4. Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements of the clinical investigation results.
• • 5. Subject has a current diagnosis of a coagulation disorder, bleeding diathesis, progressive peripheral vascular disease, post-herpetic neuralgia or uncontrolled diabetes mellitus.
• • 6. Subject has, or is scheduled to receive, implantation of another neuromodulation system (e.g. DRG or SCS system or intrathecal pump) to address their chronic pain.
• • 7. Subject has already participated in a SCS trial period before enrolling in the study.
• • 8. Subject engages in a profession or other activity that could be damaging to the wearable sensors, as determined by the investigator.
• • 9. Subject has a skin condition that could be exacerbated by use of the adhesive Anne™ sensor or the other wearables (e.g. skin allergy to adhesives, metals, plastics, hydrogels), as determined by the investigator.
• • 10. Subject has a physical condition that makes it difficult to wear the wearable sensors, as determined by the investigator.
• • 11. Subject has tremors (e.g. Parkinson's disease or Familial tremors).
• • 12. Subject has sleep/wake schedule that would present a challenge in completing all clinical site visits or in use of the wearable devices and engagement in the surveys via the mobile device.
• • 13. Subject is bedridden.
• • 14. Subject has evidence of an active disruptive psychological or psychiatric disorder or social condition as determined by the investigator.
• • 15. Subject has a current diagnosis of a progressive neurological disease as determined by the Investigator.
• • 16. Subject is immunocompromised.
• • 17. Subject has history of cancer requiring active treatment in the last 12 months.
• • 18. Subject has a documented history of substance abuse (narcotics, alcohol, etc.) or substance dependency in the 6 months prior to baseline data collection.
• • 19. Subject has life expectancy of less than 6 months.
• • 20. Subject is involved in an injury claim under current litigation.

Trial Officials